Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of carbamylated monomeric tree pollen sublingual drops in allergic rhinoconjunctivitis
2017-003063-34Phase 2Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Sep 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing Lais Frühblüher sublingual drops with Placebo (2 arms). Primary endpoint: Primary safety and tolerability endpoints. Started Sep 2017; status: completed.
02
Drugs
LAIS Frühblüher
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2017-003063-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003063-34.